Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the ...

Researchers have identified a new set of urine-based biomarkers that can accurately detect both the presence and severity of ...

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief Medic ...

Vinay Prasad, a critic of the medical mainstream, will be the next director of the FDA center that regulates vaccines and ...

We came across a bullish thesis on argenx SE (ARGX) on Substack by FluentInQuality. In this article, we will summarize the ...

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy significantly extended OS compared with chemotherapy for those with ...

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s ...

NORTHAMPTON, MA / ACCESS Newswire / May 7, 2025 / By Catharine Grimes, President of the Bristol Myers Squibb FoundationWe are in an era of unprecedented medical innovation. Scientists are making ...